Analyst Ratings For Allergan plc (NYSE:AGN)
Today, Morgan Stanley set its price target on Allergan plc (NYSE:AGN) to $202.00 per share.
There are 16 Buy Ratings, 5 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Allergan plc (NYSE:AGN) is Buy with a consensus target price of $213.0037 per share, a potential 13.13% upside.
Some recent analyst ratings include
- 8/3/2018-Allergan plc (NYSE:AGN) gets upgraded to Buy by Mizuho
- 7/26/2018-Allergan plc (NYSE:AGN) had its Hold rating reiterated by Piper Jaffray Companies with a $164.00 price target
- 7/5/2018-Allergan plc (NYSE:AGN) had its Hold rating reiterated by Argus
Recent Insider Trading Activity For Allergan plc (NYSE:AGN)
Allergan plc (NYSE:AGN) has insider ownership of 0.37% and institutional ownership of 78.87%.
- On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
- On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
- On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.
- On 3/8/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $153.96 per share and the total transaction amounting to $153,960.00.
- On 3/5/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $143.42 per share and the total transaction amounting to $129,078.00.
- On 2/21/2018 Matthew M Walsh, CFO, bought 2,000 with an average share price of $160.94 per share and the total transaction amounting to $321,880.00.
- On 2/14/2018 William Meury, Insider, sold 58,879 with an average share price of $160.62 per share and the total transaction amounting to $9,457,144.98.
About Allergan plc (NYSE:AGN)
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Recent Trading Activity for Allergan plc (NYSE:AGN)
Shares of Allergan plc closed the previous trading session at 188.29 −2.82 1.48% with shares trading hands.
